Notícias

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Companies In The Article Are:REGN,D,NEE,STX and BSX

With the study results, Boston Scientific plans a regulatory submission for the intravascular lithotripsy treatment for patients with severely calcified coronary artery disease.

Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones.

Boston Scientific (NYSE:BSX) announced a US$2b accelerated share repurchase program. The company also agreed to invest US$1.5b in MiRus, securing a significant equity stake. The MiRus deal includes an exclusive option related to the company’s transcatheter aortic valve replacement (TAVR) business. Boston Scientific, a large medical device company focused on cardiovascular and other interventional therapies, is pairing a sizeable capital return with a move deeper into structural heart...

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.45%. June E-mini S&P futures (ESM26 ) fell -0.12%, and June E-mini Nasdaq futures...

Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He

The deal gives Boston Scientific a 34% stake in MiRus and an option to buy its TAVR business for an additional $3 billion

BSX expands into fast-growing medtech segments with acquisitions spanning urology, pain management and vascular devices.

(Bloomberg) -- For years, there was only one way for mom-and-pop investors to buy into Elon Musk’s vision: shares of Tesla Inc. That’s about to change — and it’s a serious risk for Tesla investors. Most Read from BloombergStocks Fall, Oil Rises as Hormuz Deal Hopes Fade: Markets WrapBillionaire Rinehart Bets $100 Million on US Defense StocksIranian Media Said US Offered Interim Waiver on Oil SanctionsUS and Iran Far From Deal as Bond Rout Piles Pressure on TrumpWinners and Losers From Trump and

Stock Gains Following Capital Allocation AnnouncementsShares of Boston Scientific (NYSE:BSX) rose 2. 1% in premarket trading on Monday after the company announced a $2 billion accelerated share repurchase program alongside a $1.

Healthcare stocks were declining pre-bell Monday, with the State Street Health Care Select Sector SP

The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional payments totaling $3 billion.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

Moby summary of Elutia Inc.'s Q1 2026 earnings call

BSX expands global reach with strong APAC growth, FARAPULSE momentum and new approvals driving gains across Europe and China.

Boston Scientific Corporation (NYSE:BSX) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. During the lightning round, a caller asked if they should sell or buy more BSX shares. Cramer replied: I hate to sell these. I don’t mean to sound […]

Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said: For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I […]

Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. During the first quarter, the U.S. equity market declined, with the S&P 500 Index falling by 4.33%. The fixed-income sector also saw a downturn; the Bloomberg U.S. Aggregate Bond Index […]

Earlier in May 2026, Boston Scientific filed a US$565.7 million shelf registration for up to 10,000,000 common shares tied to an ESOP-related offering, while shareholders also approved charter amendments eliminating supermajority voting and adding limited officer exculpation under Delaware law. Taken together with recent director equity and deferred stock awards, these developments highlight a stronger emphasis on ownership-based incentives and refreshed corporate governance at the...

Morningstar now rates Boston Scientific (BSX) as significantly undervalued after a meaningful share price decline. The firm is flagging the stock as a potential opportunity for investors who focus on gaps between price and estimated fair value. See our latest analysis for Boston Scientific. Recent governance updates, including the removal of supermajority voting provisions and fresh director equity awards, have coincided with a sharp reset in sentiment, with the 30 day share price return down...

Boston Scientific rides on cardiovascular device growth with FARAPULSE and WATCHMAN momentum, but margin pressure and weaker estimates cloud the outlook.

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended holding Boston Scientific Corporation. “I don't understand how this thing could have fallen so fast,” he said of the medical device maker. “I know there's a lot of competition. I don't...

The latest generation of the coronary intravascular lithotripsy device is designed to be more flexible to help physicians navigate tight arteries to break up calcified deposits and restore blood flow.

Boston Scientific Corporation ( NYSE:BSX ) shareholders might have a reason to worry after multiple insiders sold their...

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Boston Scientific's Neuromodulation unit posts 15% organic sales growth in Q1, fueled by pain management gains, the acquisition of Nalu and momentum in Intracept.

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

SNN vs. BSX: Which Stock Is the Better Value Option?

Multiple securities class action lawsuits have been filed against Boston Scientific (NYSE:BSX), alleging misleading statements about the sustainability of U.S. electrophysiology growth. The cases focus on disclosures related to a key business segment and whether investors were given an accurate view of growth prospects. Several court ordered and attorney set deadlines are approaching for shareholders who may wish to participate in these actions. Boston Scientific is a large medical device...